Minerva Neurosciences (NERV)

• Market cap: $11.3M
• 1 day: -3.57%
• 5 days: -5.26%
• 1 month: -20.98%
• 3 months: -26.70%
• 6 months: -45.08%
• Year to date: -29.57%
• 1 year: -42.55%
• 5 years: -96.79%
• 10 years: -96.11%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.

Employees: 8

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

33% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 3

5% more funds holding

Funds holding: 21 [Q3] → 22 (+1) [Q4]

0.46% less ownership

Funds ownership: 30.3% [Q3] → 29.84% (-0.46%) [Q4]

18% less capital invested

Capital invested by funds: $5.65M [Q3] → $4.63M (-$1.02M) [Q4]

25% less repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 4

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $5 209% upside
• Avg. target: $5 209% upside
• High target: $5 209% upside

1 analyst rating

• positive: 0 0%
• neutral: 1 100%
• negative: 0 0%

HC Wainwright & Co. Douglas Tsao 26% 1-year accuracy 46 / 179 met price target

209% upside $5

Neutral Reiterated

26 Feb 2025